Filing search / Iovance Biotherapeutics, Inc. / "Bribery"

8-K

EX-1.1

IOVA Iovance Biotherapeutics, Inc.

20 Feb 24

Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock

5:23pm

or any applicable non-U.S. anti-bribery statute or regulation; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other

8-K

EX-1.1

IOVA Iovance Biotherapeutics, Inc.

11 Jul 23

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

4:55pm

corporate funds; (iii) violated or is in violation of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or regulation; or (iv) made

8-K

EX-1.1

vs26ec px

16 Jun 23

Entry into a Material Definitive Agreement

4:51pm

8-K

EX-1.1

lqxr6za 0xjvi11

18 Nov 22

Entry into a Material Definitive Agreement

5:19pm

8-K

EX-1.1

1s1y2guygcq a40dlnc

9 Feb 21

Entry into a Material Definitive Agreement

6:01am

8-K

EX-1.1

6981xvad9s35ckd6

29 May 20

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

4:22pm

8-K

EX-1.1

2q87d

12 Oct 18

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

4:06pm

8-K

EX-1.1

n1jd6qka6xawcumasl4v

3 Mar 15

Lion Biotechnologies Announces Public Offering of

12:00am